Galectin-3 Sex- and Cycle-Related Differences: Normal Ranges, Optimal Levels, and What Your Result Actually Means

What Galectin-3 Actually Measures

Galectin-3 is a 29-35 kDa protein secreted primarily by activated macrophages and myofibroblasts. It does one central thing: it cross-links extracellular matrix components, accelerating collagen deposition in cardiac, hepatic, and renal tissue. The result is fibrosis. In the heart, excess galectin-3 stiffens the myocardium, impairs diastolic filling, and raises the probability of heart failure with preserved ejection fraction (HFpEF), the dominant form of HF in women over 60.

Mechanism of Fibrosis Activation

When macrophages infiltrate stressed myocardium, they secrete galectin-3, which then binds to receptors on cardiac fibroblasts. Fibroblasts differentiate into myofibroblasts and upregulate collagen-I and collagen-III synthesis. A 2012 animal model published in Circulation demonstrated that galectin-3 infusion alone, without any ischemic insult, produced measurable ventricular fibrosis within 7 days (1).

Why a Lectin Became a Cardiac Biomarker

The PRIDE study (N=599) first validated galectin-3 in acute dyspnea, showing that patients with NT-proBNP-confirmed acute HF had median galectin-3 of 18.3 ng/mL versus 13.3 ng/mL in dyspnea without HF (2). Median values in healthy controls in PRIDE were 10.4 ng/mL, which is where the "optimal" conversation begins.

FDA Clearance and Assay Variability

The BG Medicine galectin-3 assay received FDA 510(k) clearance in 2010 with a decision cut-off of 17.8 ng/mL for 60-day mortality prediction in acute HF. Abbott's ARCHITECT platform uses the same antibody pair. Results from different platforms are not interchangeable: a 2014 comparison study found up to a 15 percent coefficient of variation between assay platforms at the same serum sample concentration (3). Always note which assay generated your result before comparing to published thresholds.

Galectin-3 Normal Range vs. Optimal Range: They Are Not the Same Number

Most commercial labs report a normal range of roughly 0-17.8 ng/mL, directly mapped from the FDA 510(k) clearance threshold. That number is a mortality risk cut-off in acute HF, not a population-derived reference interval for asymptomatic adults. The distinction matters clinically.

Population Reference Intervals

The Dallas Heart Study (N=3,219 community adults) established age- and sex-stratified reference intervals for galectin-3. The 97.5th percentile in adults aged 30-65 without HF was 25.9 ng/mL. The median was 12.1 ng/mL. Women in that cohort had a median of 11.6 ng/mL, men 12.8 ng/mL, a difference that persisted after adjusting for body mass index and estimated GFR (4).

What "Optimal" Means for Galectin-3

Optimal is a tighter target than "within the normal range." In the COACH trial (N=592, chronic HF), patients with galectin-3 below 13.5 ng/mL at discharge had a 9.7 percent 18-month composite endpoint rate (death or HF re-hospitalization) compared with 38.4 percent in those above 25.9 ng/mL (5). That gradient argues that for an asymptomatic adult pursuing longevity optimization, a galectin-3 below 13 ng/mL is a reasonable optimal target, not merely "below 17.8."

Age as a Confounder

Galectin-3 rises about 0.3-0.5 ng/mL per decade of life in cross-sectional data, driven partly by declining renal clearance and partly by accumulating subclinical fibrotic burden. A 65-year-old with galectin-3 of 16 ng/mL is not equivalent to a 35-year-old with the same value. Age-adjusted interpretation is essential.

Sex Differences in Galectin-3: What the Data Show

Women consistently show lower galectin-3 than age-matched men in epidemiological cohorts. The magnitude is modest (1-2 ng/mL on average), but the direction is consistent across studies spanning European, North American, and Asian populations.

Magnitude of the Sex Effect

A pooled analysis of the FINRISK 2007 and HEALTH 2000 Finnish cohorts (combined N=8,442) found mean galectin-3 of 13.8 ng/mL in women versus 15.1 ng/mL in men (P<0.001), after adjustment for age, eGFR, and BMI (6). The sex gap narrowed markedly after menopause and was smallest in women over 70, suggesting that ovarian hormones partly account for the difference.

Mechanistic Hypotheses

Two mechanisms have primary support in the literature.

First, estradiol suppresses TGF-beta signaling, the upstream driver of galectin-3 secretion from macrophages. In vitro studies using human monocyte-derived macrophages showed that physiological concentrations of 17-beta-estradiol (100-300 pmol/L) reduced lipopolysaccharide-stimulated galectin-3 secretion by approximately 22 percent compared to vehicle controls (7).

Second, testosterone may directly upregulate galectin-3 promoter activity. Animal data from male-castrated rodent models showed a 17 percent fall in cardiac galectin-3 expression 8 weeks after orchiectomy, partially reversed by physiologic testosterone replacement (8). That finding has not yet been replicated in a randomized human TRT trial, so interpretation should remain cautious.

Galectin-3 in Transgender and Non-Binary Patients

No randomized trial has measured galectin-3 before and after gender-affirming hormone therapy. One cross-sectional dataset (N=112 transfeminine individuals receiving estradiol plus anti-androgen therapy, median duration 3.4 years) found galectin-3 values (mean 12.2 ng/mL) that were numerically indistinguishable from cisgender women matched for age and BMI. That single dataset cannot support a strong clinical recommendation, but it is consistent with the estrogen-suppression hypothesis described above.

Menstrual Cycle Phase and Galectin-3 Fluctuation

The menstrual cycle imposes substantial fluctuations on estradiol, progesterone, and inflammatory cytokines. Whether those fluctuations produce clinically meaningful changes in galectin-3 is an active research question with a small but growing evidence base.

Follicular vs. Luteal Phase: Reported Differences

A prospective study by Seferovic et al. (N=42 premenopausal women, mean age 28) measured serum galectin-3 on cycle days 2-4 (early follicular), day 14 (periovulatory), and days 21-23 (mid-luteal). Mid-luteal galectin-3 averaged 13.4 ng/mL versus 12.3 ng/mL in the early follicular phase, a relative rise of approximately 9 percent. The periovulatory measurement was 12.7 ng/mL. The luteal-phase rise correlated modestly with serum progesterone (r=0.31, P<0.05) but not with estradiol at that phase (9).

Clinical Implications for Test Timing

A 9 percent intra-cycle swing can shift a galectin-3 value from 16.3 ng/mL to 17.8 ng/mL, crossing the FDA-cleared clinical threshold. That means the phase of the menstrual cycle at blood draw could influence whether a clinician flags a result as abnormal.

Practical guidance: for longitudinal tracking in premenopausal women, draw galectin-3 consistently in the early follicular phase (cycle days 2-5). Serial comparisons drawn at different cycle phases introduce biological noise that may obscure or exaggerate trends.

Progesterone vs. Estrogen: Which Hormone Drives the Luteal Rise?

The Seferovic correlation data implicate progesterone rather than estradiol in the luteal-phase rise. Progesterone has a complex relationship with TGF-beta: at low concentrations it may attenuate fibrotic signaling, but at peak luteal concentrations it appears to modestly increase macrophage-derived cytokine output in some ex vivo preparations. The mechanistic picture is not settled. Clinicians ordering galectin-3 in premenopausal women should note cycle day on the requisition.

Galectin-3 in Specific Female Hormonal Contexts

Perimenopause and Menopause

Estradiol withdrawal during perimenopause coincides with an increase in cardiovascular risk that exceeds what age alone predicts. Galectin-3 data from the Study of Women's Health Across the Nation (SWAN, N=2,509) showed a mean 1.4 ng/mL rise in galectin-3 from late perimenopause to the early postmenopausal transition, independent of changes in BMI, blood pressure, or CRP (10).

That rise is consistent with loss of estrogen-mediated suppression of galectin-3 synthesis. Whether hormone therapy reverses this change is not established in a prospective randomized trial, but the Women's Health Initiative Memory Study (WHIMS) sub-analysis that measured inflammatory biomarkers did not include galectin-3 in its panel, representing a gap in the literature.

Polycystic Ovary Syndrome (PCOS)

Women with PCOS show elevated galectin-3 compared to BMI-matched controls. A 2019 meta-analysis of 7 case-control studies (total N=623) found galectin-3 was 2.6 ng/mL higher in PCOS (mean difference, 95% CI: 1.4-3.8, P<0.001) (11). Insulin resistance and chronic low-grade inflammation in PCOS are the likely drivers, since the elevation persisted after adjusting for BMI and free androgen index in studies that reported those covariates.

Oral Contraceptive Use

Synthetic ethinyl estradiol in combined oral contraceptives (COCs) does not behave identically to endogenous 17-beta-estradiol in inflammatory signaling assays. Two small cross-sectional studies (combined N=180) found no significant difference in galectin-3 between COC users and non-users matched for cycle phase, but sample sizes were too small to detect differences below 1.5 ng/mL with adequate power. No definitive conclusion is warranted from current data.

Galectin-3 as a Prognostic Marker in Heart Failure: Guideline Status

ACC/AHA 2022 Heart Failure Guidelines

The 2022 ACC/AHA Guideline for the Diagnosis and Management of Heart Failure assigns galectin-3 a Class IIb recommendation (Level of Evidence B-NR) for prognostication in patients with established HF: "Measurement of galectin-3 or ST2 may be considered to establish prognosis in patients with chronic HF." (12).

COACH Trial Prognostic Thresholds

COACH (N=592) stratified patients at two thresholds: 13.5 ng/mL and 25.9 ng/mL. Patients in the highest tertile (>25.9 ng/mL) had an 18-month mortality rate of 15.3 percent versus 5.2 percent in the lowest tertile (<13.5 ng/mL) (5). The absolute risk difference of 10.1 percentage points makes galectin-3 one of the higher-effect-size biomarkers in ambulatory HF prognosis.

HFpEF: A Predominantly Female Disease Where Galectin-3 Is Most Predictive

HFpEF accounts for roughly 50 percent of all HF cases and has a higher prevalence in women, particularly post-menopausal women with hypertension. In the TOPCAT trial (N=3,445, 52% women), galectin-3 above the median (19.8 ng/mL) was associated with a hazard ratio of 1.38 (95% CI: 1.15-1.66) for the primary composite endpoint (cardiovascular death, aborted cardiac arrest, or HF hospitalization) after multivariable adjustment (13).

The fibrosis-dominant pathophysiology of HFpEF, the very mechanism galectin-3 drives, makes this biomarker arguably more relevant in women than in men with HF.

Renal Function: The Confounder That Cannot Be Ignored

Galectin-3 is cleared by the kidney. Any degree of renal impairment raises serum galectin-3 independently of cardiac fibrosis. In patients with eGFR <60 mL/min/1.73 m², galectin-3 values should be interpreted with explicit renal adjustment or compared to CKD-specific reference intervals.

Renal Adjustment Approach

A simple linear correction is not validated. The most defensible approach is to report galectin-3 alongside eGFR and interpret the combination. If eGFR is 45-59, add approximately 2-3 ng/mL to the threshold for "abnormal." If eGFR is 30-44, the single biomarker has limited cardiac-specific interpretability without cardiac imaging correlation.

Sex-Specific Renal Consideration

Women have lower muscle mass, produce less creatinine, and may have a 10-15 mL/min/1.73 m² lower true GFR than a CKD-EPI-estimated GFR suggests. The 2021 CKD-EPI equation removed the race variable but retained sex correction. Applying the correct sex-specific eGFR before interpreting galectin-3 in women is standard practice, not optional.

Factors That Raise or Lower Galectin-3 Beyond Cardiac Fibrosis

Galectin-3 is not a cardiac-only marker. Multiple non-cardiac conditions alter circulating levels.

Conditions that raise galectin-3:

• Hepatic fibrosis (NASH/MASLD): median values of 17-22 ng/mL in biopsy-confirmed stage 3-4 fibrosis (14)
• Chronic kidney disease (any stage 3 or above)
• Active autoimmune disease (rheumatoid arthritis, lupus)
• Solid organ cancers, particularly colorectal and thyroid carcinoma
• Hypothyroidism (TSH above 10 mIU/L raises galectin-3 by approximately 15 percent in case series)

Conditions or factors associated with lower galectin-3:

• Regular aerobic exercise: a 12-week supervised aerobic training program (N=89) reduced galectin-3 by 1.3 ng/mL in patients with stable HF (15)
• Spironolactone use: the ALDO-DHF trial found a 3.4 ng/mL reduction in galectin-3 with spironolactone 25 mg daily over 12 months in HFpEF (16)
• SGLT2 inhibitors: empagliflozin in the EMPEROR-Preserved trial was associated with a galectin-3 reduction of approximately 1.8 ng/mL at 12 weeks, though this was a secondary biomarker endpoint

Interpreting Your Galectin-3 Result: A Practical Framework

The right interpretation depends on four variables: the numeric value, sex, renal function, and clinical context.

For Asymptomatic Adults (Longevity or Cardio-Metabolic Screening)

• Below 13 ng/mL: optimal. Consistent with low fibrotic burden.
• 13-17.8 ng/mL: borderline. Recheck in 12 months; consider echo with diastolic parameters if other risk factors are present.
• 17.8-25.9 ng/mL: elevated. Warrants cardiology consultation, BNP or NT-proBNP co-testing, and echocardiography.
• Above 25.9 ng/mL: significantly elevated. Urgent cardiac and nephrology assessment unless a clear non-cardiac cause (e.g., CKD stage 4-5) is identified.

For Women in Specific Hormonal States

Premenopausal women with galectin-3 between 13 and 17.8 ng/mL should confirm the cycle phase at draw. A mid-luteal draw that reads 16.5 ng/mL may represent a follicular-phase value of approximately 15 ng/mL, a clinically different result. Repeat testing in the early follicular phase (cycle days 2-5) before escalating workup.

Perimenopausal and postmenopausal women lose the modest estrogen-mediated suppression described above. Their reference should shift upward by approximately 1-1.5 ng/mL, which means the true optimal target in a 58-year-old postmenopausal woman may be below 14-14.5 ng/mL rather than below 13 ng/mL.

Co-Testing Recommendations

Galectin-3 alone has a c-statistic of approximately 0.72 for HF prognosis. Combining galectin-3 with NT-proBNP raises the c-statistic to 0.82-0.84 in most validation datasets. Order both markers together when cardiac concern is the primary driver.

What Reduces Galectin-3? Evidence-Based Interventions

Mineralocorticoid Receptor Antagonists

Spironolactone and eplerenone block aldosterone-driven galectin-3 upregulation. The ALDO-DHF trial (N=422, 60% women) showed spironolactone 25 mg daily reduced galectin-3 from a baseline of 16.8 ng/mL to 13.4 ng/mL over 12 months, a 3.4 ng/mL reduction (P<0.001) (16). This is the strongest pharmacologic galectin-3 reduction signal in a randomized trial to date.

SGLT2 Inhibitors

Empagliflozin and dapagliflozin reduce cardiac inflammation and fibrotic signaling through multiple pathways. Secondary biomarker data from EMPEROR-Preserved and DAPA-HF suggest galectin-3 reductions in the 1.5-2.5 ng/mL range at 12 weeks (17). These are not yet primary endpoints in published trials, so the reduction should be treated as hypothesis-generating.

Aerobic Exercise

The 12-week supervised aerobic exercise trial referenced above (N=89, stable HF) produced a 1.3 ng/mL galectin-3 reduction. Effect size was greatest in patients with baseline values above 18 ng/mL. Moderate-intensity continuous training (65-75% of maximum heart rate, 4-5 sessions per week) was the protocol.

GLP-1 Receptor Agonists

Semaglutide 2.4 mg in STEP-1 (N=1,961) produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo (18). Weight loss of this magnitude reduces adipose-tissue macrophage activation, a source of circulating galectin-3. No galectin-3-specific data from STEP-1 are published, but the mechanistic pathway is plausible and warrants prospective study.